As the body of research expands on the potential of glucagon-like peptide-1 receptor agonists to address various health ...
The question of putative mechanisms of action continues to haunt psychopharmacology. Put simply, we know these drugs work, but we have very little idea how. We make guesses based on the ...
2d
GlobalData on MSNZealand Pharma steadfastly upholds amylin-based obesity drug strategyZealand’s CEO Adam Steensberg said that the company is “exactly where it wants to be” in terms of its partnering and ...
The SARS-CoV-2 pandemic interrupted much respiratory research. Respiratory clinical academics joined colleagues in providing clinical care, and global research efforts were directed to finding new ...
People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...
New research suggests that Ozempic and similar weight loss medications have the potential to be as big a game changer in addiction treatment as they have been in reducing obesity.
Insulin resistance precedes and predicts the onset of type 2 diabetes mellitus (DM2), a chronic disease that causes high morbidity and mortality worldwide. In affected people, insulin is unable to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results